Thermo Fisher Scientific Discloses How Much Clario Deal Could Add To Its EPS

Core Viewpoint - Thermo Fisher Scientific Inc. reported strong fourth-quarter results for 2025, exceeding earnings and sales expectations, indicating robust operational performance and strategic growth initiatives [1][2]. Financial Performance - Adjusted earnings for Q4 2025 were $6.57 per share, surpassing the consensus estimate of $6.45 [1]. - Quarterly sales reached $12.22 billion, a 7% increase year-over-year, exceeding the analyst consensus of $11.95 billion [1]. - Organic revenue growth was reported at 3% [1]. Segment Performance - Life Sciences Solutions sales increased by 13.1% to $2.95 billion [3]. - Analytical Instruments sales rose by 1.3% to $2.22 billion [3]. - Specialty Diagnostics revenues reached $1.22 billion, up 5.4% [3]. - Laboratory Products and Biopharma Services sales increased by 7.5% to $6.38 billion [3]. Future Guidance - For 2026, the company projects revenue growth between 4% and 6%, with expected revenue of $46.3 billion to $47.2 billion and organic growth of 3% to 4% [4]. - Adjusted earnings for 2026 are anticipated to be between $24.22 and $24.80 per share, reflecting a 6% to 8% increase compared to the consensus of $24.61 [5]. - The pending acquisition of Clario, valued at $8.875 billion, could contribute an additional 20 to 25 cents to earnings per share in 2026 [5]. Market Reaction - Following the earnings report, Thermo Fisher Scientific shares experienced a decline of 3.20%, trading at $588.57 [5].